Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 10:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 127 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: EPT Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers

NCT02670187
View directory record Official record
Conditions
Healthy
Interventions
GLS-5300
Biological
Lead sponsor
GeneOne Life Science, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of a Potential Preventive Vaccine Against HIV in Healthy Volunteers

NCT00545987
View directory record Official record
Conditions
HIV Infections
Interventions
TriGrid™ Delivery System, conventional intramuscular injection
Device
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001

NCT01403155
View directory record Official record
Conditions
Healthy
Interventions
INO-3401 + EP
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Overland Park, Kansas • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer

NCT01440816
View directory record Official record
Conditions
Merkel Cell Carcinoma
Interventions
Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS)
Biological · Device
Lead sponsor
OncoSec Medical Incorporated
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Sep 21, 2026, 10:22 PM EDT
Terminated Phase 3 Interventional

Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma

NCT00198328
View directory record Official record
Conditions
Head Neck Cancer
Interventions
Medpulser Electroporation with Bleomycin, Surgical Excision
Combination Product · Procedure
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 4 Interventional

Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer

NCT00198276
View directory record Official record
Conditions
Cancer
Interventions
MedPulser Electroporation with bleomycin
Combination Product
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Not applicable Interventional Results available

Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the BWI IRE Ablation System

NCT05293639
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Pulse Field Ablation
Device
Lead sponsor
Biosense Webster, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 1 Interventional

Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults

NCT01266616
View directory record Official record
Conditions
HIV Infections
Interventions
Profectus HIV MAG pDNA vaccine, IL-12, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 21, 2026, 10:22 PM EDT
Not listed No phase listed Observational

Pancreatic Cancer & Surgical Resection

NCT05170802
View directory record Official record
Conditions
Pancreas Cancer
Interventions
NanoKnife procedure
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 1 Interventional Results available

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

NCT03835533
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
NKTR-214 (Cohort A), Nivolumab (Cohort A, B and C), Stereotactic body radiation therapy (SBRT) (Cohort B), CDX-301 (Cohort B and C), Poly-ICLC (Cohort B), INO-5151 (Cohort C), Cellectra 2000
Drug · Radiation · Device
Lead sponsor
Parker Institute for Cancer Immunotherapy
Other
Eligibility
18 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Sep 21, 2026, 10:22 PM EDT
Active, not recruiting No phase listed Observational

A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer

NCT03899649
View directory record Official record
Conditions
Stage III Pancreatic Cancer
Interventions
SOC, NanoKnife System
Drug · Device
Lead sponsor
Angiodynamics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
14
States / cities
La Jolla, California • Gainesville, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Therapeutic Vaccination in Treated HIV Disease

NCT03606213
View directory record Official record
Conditions
HIV-1-infection
Interventions
PENNVAX-GP, INO-6145, INO-9012, CELLECTRA® 2000
Biological · Device
Lead sponsor
Steven Deeks
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

NCT03185013
View directory record Official record
Conditions
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
Interventions
VGX-3100, Placebo, Electroporation (EP)
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
22
States / cities
Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults

NCT01142362
View directory record Official record
Conditions
Healthy
Interventions
VGX-3400X
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Overland Park, Kansas • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Sep 21, 2026, 10:22 PM EDT
Active, not recruiting Phase 4 Interventional

Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias

NCT06765356
View directory record Official record
Conditions
Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Long-standing Persistent Atrial Fibrillation
Interventions
Farapulse Catheter System, Low-dose Colchicine
Device · Drug
Lead sponsor
Vivek Reddy
Other
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Jonesboro, Arkansas • Ventura, California • Naples, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 21, 2026, 10:22 PM EDT
Terminated Phase 2 Interventional Results available

Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat

NCT03823131
View directory record Official record
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma
Interventions
ImmunoPulse, Epacadostat, Pembrolizumab, CORVax, Tavokinogene telseplasmid
Device · Drug · Biological
Lead sponsor
Chase Heaton, MD
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 1 Interventional

Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100

NCT01188850
View directory record Official record
Conditions
Human Papillomavirus (HPV)
Interventions
VGX-3100
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 46 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Hopwood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Sep 21, 2026, 10:22 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma

NCT01579318
View directory record Official record
Conditions
Cutaneous T Cell Lymphomas (CTCL), Mycosis Fungoides (MF)
Interventions
Tavokinogene Telseplasmid (tavo), OncoSec Medical System (OMS)
Biological · Device
Lead sponsor
OncoSec Medical Incorporated
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Sep 21, 2026, 10:22 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia

NCT04131413
View directory record Official record
Conditions
Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III
Interventions
pNGVL4aCRTE6E7L2
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
19 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2029
U.S. locations
2
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

NCT03180684
View directory record Official record
Conditions
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia, Vulvar Intraepithelial Neoplasia (VIN), VIN2, VIN3, Pre-cancerous Lesions of the Vulva, Human Papillomavirus (HPV)
Interventions
VGX-3100, Imiquimod 5% Cream, CELLECTRA™ 2000
Biological · Drug · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Newark, Delaware • Augusta, Georgia • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

dMAbs for Prevention of COVID-19

NCT05293249
View directory record Official record
Conditions
Healthy Volunteers
Interventions
dMAb AZD5396, dMAb AZD8076, CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device, Hylenex, CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device
Combination Product · Drug
Lead sponsor
Pablo Tebas
Other
Eligibility
18 Years to 60 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 21, 2026, 10:22 PM EDT
Completed Phase 1 Interventional

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

NCT03532217
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer
Interventions
PROSTVAC-V, PROSTVAC-F, Nivolumab, Ipilimumab, Neoantigen DNA vaccine, TriGrid Delivery System, Tumor biopsy, Peripheral blood, Fecal samples, Leukapheresis
Biological · Drug · Device + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Sep 21, 2026, 10:22 PM EDT
Active, not recruiting Phase 2 Interventional

Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases

NCT03856658
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Liver Metastases
Interventions
Floxuridine (FUDR), Hepatic Artery Infusion Pump, Heparinized Saline
Drug · Device
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 21, 2026, 10:22 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Neoantigen Vaccine in Solid Tumors

NCT03914872
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
Neoantigen DNA Vaccine, Integrated electroporation device
Biological · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 21, 2026, 10:22 PM EDT